Diabetes treatment and control: the effect of public health insurance for the poor in Mexico
Sandra G Sosa-Rubí, Omar Galárraga & Ruy López-Ridaura
Volume 87, Number 7, July 2009, 512-519
Table 3. Average effect of enrolment in the Seguro Popular in terms of diabetes treatment and control, Mexico, 2006a
|Seguro Popular||Uninsured||Unmatched differenceb||t-value||P-value||Matched ATTc (95% CI)||t-value||P-value|
|Health care access outcome|
|Regular use of any blood glucose control testd||0.809||0.754||0.055||2.300||***||0.095 (0.020‑0.161)||2.626||***|
|No. of insulin users||0.0415||0.0479||–0.0064||–0.504||NS||0.001 (–0.032–0.034)||0.066||NS|
|No. of insulin shots per week among insulin users||12.6||8.99||3.600||2.922||***||3.133 (0.04–6.22)||1.988||**|
|No. of blood sugar control tests per month||1.02||0.87||0.144||0.825||NS||0.142 (0.024–0.260)||2.371||***|
|Four or more physician visits per year||0.918||0.811||0.107||4.795||***||0.093 (0.032–0.154)||3.019||***|
|Proportion of diabetics with appropriate glucose controle||0.089||0.074||0.015||0.624||NS||0.056 (0.009–0.103)||2.316||***|
|Proportion of diabetics with very poor glucose controlf||0.367||0.462||–0.095||–2.122||***||–0.175 (–0.285–0.065)||–3.159||***|
**P < 0.05; ***P < 0.01, using t tests, of mean differences between treatment and control (unmatched and matched) groups.ATT, average treatment effect on the treated; CI, confidence interval; NS, not significant.
a The data are not weighted.
b This is the raw difference between unmatched samples, or the difference between the mean observed in Seguro Popular enrollees and the mean observed in the uninsured population.
c The ATT is based on the differences in mean outcome for propensity-score-matched individuals using nearest neighbour matching.
d Tests may include urine or capillary blood reactive strips, blood glucose, or glycosylated haemoglobin (HbA1c).
e Appropriate glucose control (HbA1c ≤ 7%) compared with poor glucose control (HbA1c > 7%).
f Very poor glucose control (HbA1c > 12%) compared with normal and poor glucose control (HbA1c ≤ 12%).